US-APR2020 is a probiotic formulation intended to restore the
gut bacteria balance to improve the removal of uremic toxins in the bowel in CKD
patients. This Phase 2b study is to evaluate the safety and efficacy of the probiotics
in the management of patients with CKD Stage IV.